The FDA is moving toward real-time clinical trial data review, using new technologies to reduce reporting lag for regulators. The agency plans to start with oncology studies led by Amgen and AstraZeneca as part of proof-of-concept efforts. The shift centers on how sponsors and the FDA handle data accrual, submission cadence, and review timing rather than waiting for traditional end-of-study packages. The FDA has indicated it will build on these pilots toward a broader real-time framework. For trial operations, the move increases the importance of data interoperability and governance planning early in protocol design, especially for oncology programs that may depend on faster evidence interpretation to support regulatory decisions.